Home Equities Score Tiziana Life Sciences Inc. (TLSA) stock surged during pre-market. Let’s see why?

Tiziana Life Sciences Inc. (TLSA) stock surged during pre-market. Let’s see why?

Tiziana Life Sciences Inc. (NASDAQ: TLSA) stock declined by 2.54% at last close however the TLSA stock price depicts a rise of 8.26% during the pre-market trading session. Tiziana Life Sciences is a biotech business based in the United Kingdom that focuses on the research and development of new compounds to treat cancer and immunology in humans.

>> 7 Top Picks for the Post-Pandemic Economy << 

Significant Development

Tiziana Life Sciences has inked a deal to perform a Phase 2 Proof-of-Concept research in Brazil with FHI Clinical which is a worldwide clinical contract research organization (CRO). Its goal is to see if intranasal Foralumab is safe, tolerable, and effective in hospitalized patients with chronic coronavirus disease 2019 (COVID-19) and pulmonary inflammation.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Foralumab will be administered intranasally using a metered-dose nasal atomization device in this clinical study. Nasal administration of Foralumab is a cutting-edge treatment option for individuals with autoimmune disorders in whom the immune system has become deregulated. Numerous studies have shown that people with COVID-19 have immune system dysfunction.

This concrete evidence research will build on initial results of safety, tolerability, and effectiveness of intranasal administration of Foralumab in mild to severe non-hospitalized COVID-19 individuals. It will be randomized, placebo-controlled, and double-blind. As a result, this study will look at the attenuation of pulmonary pathology in hospitalized COVID-19 patients. This research will be placed at up to seven different locations across Brazil. The study will include 80 hospitalized patients with severe COVID-19 and evidence of lung involvement on a computed CT scan at screening.

Intranasal Foralumab 100 g will be given to patients in a 1:1 ratio. Following 14 days of intranasal treatment, the researchers will assess the efficacy of Foralumab on symptom alleviation by chest CT, inflammatory biomarkers, T-cell subpopulations, safety, and mucosal inflammatory response.

>> 7 Top Picks for the Post-Pandemic Economy << 

Ted FitzGerald, FHI Clinical President and CEO stated,

FHI is particularly qualified to meet the demands of this Phase 2 study because they can build on previous epidemic expertise, such as quick study start-up in research-naive areas, utilizing existing worldwide research networks, and contributing to local health systems. They’re experts in dealing with the complexities of infectious disease studies, which need meticulous preparation and contingency planning.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Energous Corporation Inc. (WATT) stock declines during after-market. Here’s to know why?

Energous Corporation Inc. (WATT) stock gained by 7.05% at last close whereas the WATT stock price plunged by 7.82% in the after-hours trading session....

AMAZON Inc. (AMZN) stock fell during after-market. Here’s the update

Amazon Inc. (NASDAQ: AMZN) stock plunged by 0.84% at last close however moving ahead the AMZAN share price also declines by 7.44% in the...

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused...

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

ImmunoPrecise Inc. (IPA) stock fell during pre-market. What’s the update?

ImmunoPrecise Inc. (NASDAQ: IPA) stock declined by 8.39% at last close while the IPA stock-price plunge by 4.87% in pre-market as well. ImmunoPrecise is...

ECMOHO Ltd. (MOHO) stock plunged during pre-market. Let’s see what’s happening?

ECMOHO Ltd. (NASDAQ: MOHO) stock gained by 7.05% at last close, while during pre-market MOHO stock has been seen declining by 7.75%. In China's...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

Related News

UXIN stock declines during current market trading. What’s driving it low?

Uxin Ltd. (NASDAQ: UXIN) stock declines by 3.41% during current market trading. In China, Uxin Limited is a prominent online used vehicle dealer with...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

Why did Atossa Therapeutics Inc. (ATOS) underperform on Thursday?

Atossa Therapeutics Inc. (ATOS) shares fell 5.38% in after-hours on Thursday, July 29, 2021, and closed the daily trading at $3.69 per share. Earlier...

Why Ardelyx Inc. (ARDX) stock price fluctuated on Thursday?

Ardelyx Inc. (ARDX) shares jumped 2.92% in after-hours on Thursday, July 29, 2021, and closed the daily trading at $1.76. Earlier in the regular...

Annovis Bio Inc. (ANVS) stock plunged during current market. Here’s the update

Annovis Bio Inc. (NASDAQ: ANVS) stock declined by 51.30% in the current market trading session. Annovis Bio based in Berwyn, Pennsylvania, is a clinical-stage...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam